{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infectious+Disorder&page=33", "query": { "condition": "Infectious Disorder", "page": 33 }, "page_size": 10 }, "pagination": { "page": 33, "page_size": 10, "total_count": 8615, "total_pages": 862, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infectious+Disorder&page=34&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infectious+Disorder&page=32&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T01:49:45.044Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00002183", "title": "A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Amprenavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-27T01:49:45.044Z", "location_count": 3, "location_summary": "San Diego, California • Denver, Colorado • Atlanta, Georgia", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002183" }, { "nct_id": "NCT00002154", "title": "A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cognitive Disorders", "HIV Infections" ], "interventions": [ { "name": "Thioctic acid", "type": "DRUG" }, { "name": "Selegiline hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Dana Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-27T01:49:45.044Z", "location_count": 3, "location_summary": "Baltimore, Maryland • New York, New York • Rochester, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002154" }, { "nct_id": "NCT00001108", "title": "A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Ritonavir", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" }, { "name": "Nevirapine", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "22 Years", "sex": "ALL", "summary": "4 Years to 22 Years" }, "enrollment_count": 6, "start_date": null, "completion_date": "2000-06", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-27T01:49:45.044Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • Miami, Florida + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001108" }, { "nct_id": "NCT04666025", "title": "SARS-CoV-2 Donor-Recipient Immunity Transfer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Accelerated Phase CML, BCR-ABL1 Positive", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Phase CML, BCR-ABL1 Positive", "COVID-19 Infection", "Hematopoietic and Lymphoid Cell Neoplasm", "Hodgkin Lymphoma", "Lymphoblastic Lymphoma", "Myelodysplastic Syndrome", "Myelofibrosis", "Myeloproliferative Neoplasm", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Diagnostic Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2020-09-23", "completion_date": "2023-05-05", "has_results": false, "last_update_posted_date": "2024-04-08", "last_synced_at": "2026-10-27T01:49:45.044Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666025" }, { "nct_id": "NCT02850276", "title": "Autonomic Neuropathy, GI Motility, and Inflammation in HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "HIV Disease" ], "interventions": [ { "name": "Pyridostigmine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2015-11", "completion_date": "2018-06-01", "has_results": true, "last_update_posted_date": "2019-05-29", "last_synced_at": "2026-10-27T01:49:45.044Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02850276" }, { "nct_id": "NCT01425970", "title": "Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "INX-08189", "type": "DRUG" }, { "name": "Placebo matching with INX-08189", "type": "DRUG" }, { "name": "Pegylated interferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Daclatasvir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 210, "start_date": "2012-05", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-10-27T01:49:45.044Z", "location_count": 6, "location_summary": "Anaheim, California • La Jolla, California • San Francisco, California + 3 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT01425970" }, { "nct_id": "NCT00632970", "title": "Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" }, { "name": "Lopinavir/Ritonavir", "type": "DRUG" }, { "name": "Truvada", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George Washington University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2008-02", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2018-08-29", "last_synced_at": "2026-10-27T01:49:45.044Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00632970" }, { "nct_id": "NCT03299205", "title": "Alcohol & Metabolic Comorbidities in PLWHA: Evidence Driven Interventions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV/AIDS", "Dysglycemia", "Alcohol Use Disorder" ], "interventions": [ { "name": "Exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Louisiana State University Health Sciences Center in New Orleans", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2017-11-20", "completion_date": "2023-09-15", "has_results": false, "last_update_posted_date": "2023-10-03", "last_synced_at": "2026-10-27T01:49:45.044Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03299205" }, { "nct_id": "NCT03489629", "title": "STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Trimethoprim Sulfamethoxazole (TMP/SMX)", "type": "DRUG" }, { "name": "Minocycline", "type": "DRUG" }, { "name": "Mupirocin", "type": "DRUG" }, { "name": "Chlorhexidine Gluconate", "type": "DRUG" }, { "name": "Environmental Decontamination", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "2 Years to 45 Years" }, "enrollment_count": 49, "start_date": "2018-04-03", "completion_date": "2026-01-31", "has_results": true, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-27T01:49:45.044Z", "location_count": 9, "location_summary": "Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 6 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03489629" }, { "nct_id": "NCT00002272", "title": "An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Herpes Simplex", "HIV Infections" ], "interventions": [ { "name": "Foscarnet sodium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astra USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-10-27T01:49:45.044Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002272" } ] }